0000000000928248

AUTHOR

Salvatrice Mancuso

showing 98 related works from this author

Rituximab for Immune Thrombocytopenia: A Retrospective Analysis on the Role of Prophylaxis Against Pneumocystis Jirovecii and Herpes Zoster Virus

2018

Abstract Introduction and objective of the study Rituximab (RTX) is considered a valid second line treatment option for persistent or chronic Immune Thrombocytopenia (ITP). RTX is known to affect the immune system thus increasing the risk for viral and fungal infections. Although prophylactic treatment to prevent Pneumocystis jirovecii (PJ) and herpes viruses' infections is used in patients with haematological neoplasms receiving RTX, these evidence is lacking in ITP patients candidated to anti-CD20 therapy. We here reported the role of phrophylaxis in a cohort of patients treated with RTX for refractory/relapsed ITP. Methods Data from patients affected by ITP and treated at our Institution…

medicine.medical_specialtybiologymedicine.diagnostic_testbusiness.industrySulfamethoxazoleImmunologyComplete blood countAzathioprineCell BiologyHematologybiology.organism_classificationBiochemistryTrimethoprimRegimenInternal medicineCohortmedicinePneumocystis jiroveciiRituximabbusinessmedicine.drugBlood
researchProduct

Cardio-oncology in multiple myeloma: is it time for a specific focus?

2017

It has been known for some time that some oncologic drugs can cause heart damage. The term ‘cardiotoxicity’ just refers to the presence of a cardiac event during therapy or at least related to ther...

Cardiovascular eventCancer Researchmedicine.medical_specialtyHeart DiseasesInterdisciplinary ResearchAntineoplastic Agents030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineHumansCardio oncologyIntensive care medicineMultiple myelomaFocus (computing)Cardiotoxicitybusiness.industryDisease Managementfood and beveragesHematologymedicine.diseaseCardiotoxicityhumanitiesCardio-oncologyOncologyMultiple MyelomabusinessHeart damage030215 immunology
researchProduct

Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario

2019

medicine.medical_specialtyVenous thrombosisbusiness.industryInternal medicineAcquired hemophiliaAcquired haemophilia high inhibitor venous thrombosisMedicineGeneral MedicinebusinessBypassing agentmedicine.diseaseGastroenterologyAnnals of Hematology & Oncology
researchProduct

Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observ…

2019

Introduction: Ultrasound (US) assessment of joints is an evolving point of care tool for the detection of early joint arthropathy (Napolitano M, Kessler CM. Hemophilia A and B. Consultative Hemostasis and Thrombosis, Kitchens, 4th edition); population pharmacokinetic (pop-PK) studies are adopted as a useful instrument to set the prophylaxis regimen for patients with hemophilia, they may improve adherence (Nagao A.et al. Thromb Res. 2019 Jan; 173:79-84) and reduce the annual bleeding rate (ABR). Adherence to continuous intravenous administrations of factor VIII or Factor IX products is challenging, thus patients may experience breakthrough bleedings while on prophylaxis. Repeated US examinat…

Health related quality of lifemedicine.medical_specialtybusiness.industryTreatment adherenceImmunologyCell BiologyHematologyBiochemistryHemophiliasmedicineObservational studyIn patientAdherence to treatment haemophilia Apoint of careIntensive care medicinebusinessProspective cohort studyPoint of careFactor IXmedicine.drug
researchProduct

Oral leishmaniasis in an HIV-infected patient.

2000

As in most countries in the Mediterranean basin, leishmaniasis is endemic in Italy, where it has visceral (VL) and cutaneous (CL) forms caused by viscerotropic and dermotropic strains of Leishmania infantum, respectively. With the spread of the acquired immunodeficiency syndrome (AIDS) epidemic, the number of coinfections with Leishmania and human immunodeficiency virus (HIV) is increasing. Between 35% and 50% of the adult VL cases diagnosed annually in Sicily from 1991 to 1995 were related to HIV [1]; although cases of coinfection have been reported in 28 countries worldwide, the majority of these cases (1440 from 1990 to 1998) have been notified in four countries (Spain, Italy, France, Po…

Microbiology (medical)AdultLeishmaniasis MucocutaneousMaleHIV InfectionsAcquired immunodeficiency syndrome (AIDS)medicineHumansSidaLeishmaniasisbiologyLamivudineLeishmaniasisGeneral MedicineMiddle Agedmedicine.diseasebiology.organism_classificationLeishmaniaVirologyInfectious DiseasesImmunologyCoinfectionFemaleViral diseaseLeishmania infantumMouth Diseasesmedicine.drugEuropean journal of clinical microbiologyinfectious diseases : official publication of the European Society of Clinical Microbiology
researchProduct

Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognosti…

2023

Background: In this single center study, we retrospectively evaluated the calculated hemorheological profile in patients with a new diagnosis of multiple myeloma, with the aim to evaluate possible relationships with some prognostic predictors, such as ISS, albumin levels, beta2-microglobulin, red cell distribution width, and bone marrow plasma cell infiltration. Methods: In a cohort of 190 patients, we examined the calculated blood viscosity using the de Simone formula, and the albumin/fibrinogen ratio as a surrogate of erythrocyte aggregation, and then we related these parameters to prognostic factors, using the Kruskal–Wallis and the Mann–Whitney tests, respectively. Results: From our ana…

multiple myelomahemorheological patternmultiple myeloma; hemorheological pattern; calculated blood viscosity; albumin/fibrinogen ratio; prognostic factorsalbumin/fibrinogen ratioMedicine (miscellaneous)prognostic factors.calculated blood viscosityGeneral Biochemistry Genetics and Molecular BiologyBiomedicines; Volume 11; Issue 3; Pages: 964
researchProduct

T Cell Large Granular Lymphocytic Leukemia in Association with Sjögren’s Syndrome

2009

T cell large granular lymphocytic (LGL) leukemia is a rare condition accounting for 2–3% of all mature lymphoid leukemias. Here, we present the case of a 73-year-old woman presenting with neutropenia and anemia (hemoglobin 9.9 g/dl). Hematological assessment revealed the presence of a T cell LGL leukemia. At the time of T cell LGL leukemia diagnosis, the patient developed xerophthalmia and xerostomia, and a diagnosis of Sjögren’s syndrome was made following salivary gland biopsy. The finding of large granular lymphocytes in the context of autoimmune disorders is well-known, though it often occurs with rheumatoid arthritis or in association with a positive autoantibody titer in the absence o…

LGL leukemiaNeutropeniaT cellchemical and pharmacologic phenomenaContext (language use)Settore MED/08 - Anatomia PatologicaNeutropeniamedicine.disease_causeAutoimmune DiseasesSettore MED/15 - Malattie Del SangueAutoimmunityhemic and lymphatic diseasesmedicineHumansAgedbusiness.industryAutoantibodyAnemiaHematologyGeneral Medicinemedicine.diseaseLymphomaLeukemia Large Granular LymphocyticLeukemiaSjogren's Syndromemedicine.anatomical_structureRheumatoid arthritisImmunologyFemalebusinessImmunosuppressive AgentsActa Haematologica
researchProduct

COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS AND POLYCYTHEMIA VERA.

2017

Polycythemia vera Haplotype analysis erythrocytosis
researchProduct

Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies

2018

Abstract Cryopreservation for the long-term storage of platelets (PLTs) is a useful method to overcome the limits of platelet shortage. This is an in vitro prospective study to evaluate the count, viability, and function of buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at −80 °C with a modified Valeri method. PLTs were stored in 6% DMSO with a patented kit. Overall, 49 BC-PLTs from 245 healthy volunteer donors were prepared, cryopreserved, and analysed before and after 3, 6, and 9 months of storage. In flow cytometry, a statistically significant reduction in CD 42b (92.7 ± 4.29% at T0 vs. 23.6 ± 27.5% at T3…

Blood PlateletsCryopreservationmedicine.diagnostic_testChemistryIn vitro studyEconomic shortageHematologyBuffy coat030204 cardiovascular system & hematologyCryopreserved plateletThrombin generationCryopreservationIn vitroFlow cytometryAndrology03 medical and health sciences0302 clinical medicineViabilityBlood Buffy CoatHealthy volunteersmedicineHumansPlateletDMSO030215 immunologyTransfusion and Apheresis Science
researchProduct

Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving mode…

2011

PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting …

MaleQuinuclidinesmedicine.medical_treatmentCINVCHOPGastroenterologyDexamethasoneSettore MED/15 - Malattie Del SangueAntineoplastic Combined Chemotherapy ProtocolsSerotonin 5-HT3 Receptor AntagonistsProspective StudiesAged 80 and overLymphoma Non-HodgkinPalonosetronNauseaMiddle AgedEmesisPalonosetronTreatment OutcomeOncologyAnesthesiaCHOP CINV Emesis Nausea NHL PalonosetronVomitingFemaleOriginal Articlemedicine.symptomCHOP-CINV; emesis; nausea; NHL; Palonosetronmedicine.drugAdultmedicine.medical_specialtyVomitingNauseamedicine.drug_classNHLYoung AdultInternal medicinemedicineHumansAntiemeticGlucocorticoidsAgedChemotherapybusiness.industryIsoquinolinesmedicine.diseaseNon-Hodgkin's lymphomaAntiemeticsbusinessCHOPChemotherapy-induced nausea and vomiting
researchProduct

Lymphomas and thyroid: Bridging the gap

2018

The thyroid gland is often involved in the development of neoplastic diseases, including lymphoproliferative disorders. The aim of this paper is to provide a comprehensive overview of the multiple interactions between lymphoma and thyroid. Through an extensive research among the literature, the relationship between lymphomas and thyroid can be established at various levels, and the possible interconnections are here summarized in 5 points: (1) the greater risk of lymphoma development in some thyroid diseases; (2) the primary thyroid lymphoma, with focus on issues related to the diagnosis, differential diagnosis, and treatment; (3) the incidence of thyroid involvement in primitive nodal lymp…

OncologyCancer Researchmedicine.medical_specialtythyroid incidentalomamedicine.medical_treatmentLymphoproliferative disorders030209 endocrinology & metabolismMalignant disease03 medical and health sciences0302 clinical medicineHashimoto's thyroiditiThyroid lymphomahemic and lymphatic diseasesInternal medicinemedicineIn patientprimary thyroid lymphomabusiness.industryThyroidHematologyGeneral Medicineradio and immuno-chemotherapymedicine.diseaseLymphomasecondary thyroid lymphomaRadiation therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisDifferential diagnosisbusiness
researchProduct

Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory dr…

2015

The absolute lymphocyte count (ALC) has been widely studied in hematologic and solid malignancies as a marker of host antitumor immunity. Its significance has been evaluated in multiple myeloma (MM...

Aged 80 and overMaleCancer ResearchAntitumor immunitybusiness.industryAbsolute lymphocyte countAntineoplastic AgentsHematologyNewly diagnosedMiddle AgedPrognosismedicine.diseaseOncologyImmunologyOverall survivalHumansImmunologic FactorsMedicineFemaleLymphocyte CountAbsolute lymphocyte count multiple meyolmaMultiple MyelomabusinessMultiple myelomaAgedLeukemia & Lymphoma
researchProduct

Cardiovascular risk factor in MPN patients

2020

Malemedicine.medical_specialtyMyeloproliferative DisordersHematologybusiness.industryThrombosisHematologyMiddle AgedCardiovascular riskSettore MED/15 - Malattie Del SangueText miningCardiovascular DiseasesHeart Disease Risk FactorsInternal medicineHumansMedicineFemaleRisk factorCardiology and Cardiovascular MedicinebusinessAgedJournal of Thrombosis and Thrombolysis
researchProduct

Genetic Diversity of HIV-1 Non-B Strains in Sicily: Evidence of Intersubtype Recombinants by Sequence Analysis ofgag,pol, andenvGenes

2007

The molecular epidemiology of HIV-1 strains in Sicily (Italy) was phylogenetically investigated by the analysis of HIV-1 gag, pol, and env gene sequences from 11 HIV-1 non-B strains from 408 HIV-1-seropositive patients observed from September 2001 to August 2006. Sequences suggestive of recombination were further investigated by bootscanning analysis of various fragments. Overall, we identified several second-generation recombinant (SGRs) strains, which contained genetic material of CRF02_AG in at least one gene. Notably, three individuals were found to be infected with subsubtype A3, and one of them showed genetic recombination with subsubtype A4. The current study emphasizes the genetic a…

AdultMaleSUBTYPE-ASequence analysisMolecular Sequence DataImmunologyGene Products gagGene Products polHIV InfectionsBiologySettore MED/42 - Igiene Generale E ApplicataGenetic recombinationGenetic analysisCRF02-AGlaw.inventionSUPERINFECTIONANTIRETROVIRAL THERAPYMOLECULAR EPIDEMIOLOGYlawVirologyHumansPHYLOGENETIC ANALYSISSicilyGeneWEST-AFRICAAgedRecombination GeneticGeneticsGenetic diversityCOMPLEXMolecular epidemiologyStrain (biology)Gene Products envGenetic Variationvirus diseasesSequence Analysis DNAMiddle AgedIMMUNODEFICIENCY-VIRUS TYPE-1VirologyInfectious DiseasesHIV-1CAMEROONRecombinant DNAFemaleAIDS Research and Human Retroviruses
researchProduct

Comparison between whole blood viscosity measured and calculated in subjects with monoclonal gammopathy of undetermined significance and in patients …

2021

BACKGROUND: in this study, with a re-evaluation of the hemorheological determinants previously described in MGUS subjects and in MM patients, we have detected the calculated whole blood viscosity, according whether to the hematocrit and total plasma protein concentration (de Simone formula) or to the haematocrit and plasma fibrinogen level (Merrill formula), and a marker of the erythrocyte aggregation (albumin/fibrinogen level). METHODS: data were expressed as means±standard deviation. Student’s t test for unpaired data was used to compare MGUS subjects and MM patients. The correlation coefficient between mean erythrocyte aggregation (MEA) and hematocrit (Ht) was evaluated in MGUS, MM and M…

Erythrocyte Aggregationmedicine.medical_specialtyPhysiologyBlood viscosityUrologyParaproteinemias030204 cardiovascular system & hematologyHematocritFibrinogenErythrocyte aggregationMonoclonal Gammopathy of Undetermined Significance03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesPhysiology (medical)medicineHumansCalculated whole blood viscosity measured whole blood viscosity hematocrit total plasma protein albumin fibrinogenMultiple myelomamedicine.diagnostic_testChemistryAlbuminFibrinogenWhole blood viscosityHematologymedicine.diseaseBlood ViscosityHematocrit030220 oncology & carcinogenesisCardiology and Cardiovascular MedicineMultiple MyelomaMonoclonal gammopathy of undetermined significancemedicine.drugClinical hemorheology and microcirculation
researchProduct

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep

2020

The Essential Thrombocythemia is a Chronic Philadelphia-negative Myeloproliferative Neoplasm characterized by a survival curve that is only slightly worse than that of age- and sex-adjusted healthy population. The criteria for diagnosis were reviewed in 2016 by WHO. The incidence varies from 0.2 to 2.5:100 000 people per year, with a prevalence of 38 to 57 cases per 100 000 people. The main characteristics of ET are the marked thrombocytosis and the high frequency of thrombosis. The spectrum of symptoms is quite wide, but fatigue results to be the most frequent. Thrombosis is frequently observed, often occurring before or at the time of diagnosis. The classification of thrombotic risk has …

Plateletsmedicine.medical_specialtylcsh:RC633-647.5Essential thrombocythemiabusiness.industryPlateletlcsh:Diseases of the blood and blood-forming organsHematologyReviewMyeloproliferative Neoplasmmedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisDigInternal medicinemedicineMyeloproliferative NeoplasmsThrombocythemiabusinessSurvival analysisMyeloproliferative neoplasm030215 immunologySlightly worse
researchProduct

The difference of free light chains as a predictor of kidney damage in patients with Multiple Myeloma

2022


 Background: Multiple myeloma (MM) is a malignant neoplasm characterized by the clonal expansion of plasma cells that can release monoclonal immunoglobulins (monoclonal component) or part of theme. Since 2001, the k and λ serum free light chains (sFLC) evaluation and their ratio (rFLC) have made up the laboratory analysis more sensitive and precise in MM patients. The role of rFLC has been widely studied and discussed and now it is validated in the literature. Instead, the value of free light chains difference (dFLC), especially in MM is less known yet. The aim of this study is to evaluate the relationship between the dFLC and the kidney damage parameters in patients with MM, in compa…

lcsh:R5-920medicine.medical_specialtyKidneyCreatinineeducation.field_of_studyProteinuriabusiness.industrylcsh:Public aspects of medicinePopulationUrologyRenal functionlcsh:RA1-1270medicine.diseaseImmunoglobulin light chainMultiple Myeloma free light chains difference free light chains ratio renal damagechemistry.chemical_compoundmedicine.anatomical_structurechemistrymedicineAlbuminuriamedicine.symptomlcsh:Medicine (General)businesseducationMultiple myelomaEpidemiology, Biostatistics, and Public Health
researchProduct

Presence of human papillomavirus and Epstein-Barr virus in the cervix of women infected with the human immunodeficiency virus

2001

The presence of human papillomavirus (HPV) and Epstein-Barr virus (EBV) was sought in cervical scrapings from 110 human immunodeficiency virus (HIV)-infected women to evaluate the role of these viruses as risk factors for squamous intraepithelial lesions of the cervix. By using PCR, presence of HPV-DNA and EBV-DNA was found in 60.9% (67/110) and in 10% (11/110) of clinical samples, respectively. Identification of oncogenic group of HPV by hybrid capture (HC II, Murex-Digene) indicated the presence of low-risk HPV in 13 (19.4%) patients, high-risk HPV in 28 (41.8%), and both types of HPV in 26 (38.8%) patients. Squamous intraepithelial lesions were present in 59 cases, being low-grade (n = 5…

Opportunistic infectionHuman immunodeficiency virus (HIV)medicine.disease_causeVirusHerpesviridaelaw.inventionlawVirologymedicineGammaherpesvirinaeHuman papillomavirusRisk factorSidaCervixPolymerase chain reactionbiologybusiness.industryObstetrics and GynecologyGeneral Medicinebiology.organism_classificationmedicine.diseaseEpstein–Barr virusVirologyKoilocyteInfectious Diseasesmedicine.anatomical_structureViral diseasebusinessJournal of Medical Virology
researchProduct

Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literatu…

2021

Ruxolitinib side effects include the most frequent hematological toxicity along with a more recently evidenced immunosuppressive activity, interfering both with the innate and adaptive immunity, and several cases of reactivation of latent infections by opportunistic agents in patients in treatment with ruxolitinib have been published in the last years. Several pathophysiological mechanisms may explain an association between ruxolitinib and opportunistic infections. From what we know, the only case of an isolated lymph node TBC reactivation in a ruxolitinib-treated myelofibrosis (MF) patient was reported by Patil et al. in 2016 [Int J Med Sci Public Health. 2017;6(3):1]. Other 10 cases descr…

Oncologymedicine.medical_specialtyRuxolitinibConstitutional symptomsSettore MED/15 - Malattie Del SangueHematological toxicityInternal medicineDrug DiscoverymedicinePharmacology (medical)In patientMyelofibrosisProspective cohort studyLymph nodePharmacologybusiness.industryInfection Myelofibrosis Reactivation Tuberculosis Ruxolitinib TBCGeneral Medicinemedicine.diseaseInfectious Diseasesmedicine.anatomical_structureOncologySputummedicine.symptombusinessmedicine.drug
researchProduct

Monocyte and lymphocyte apoptosis resistance in acute and chronic brucellosis and its possible implications in clinical management.

2003

This study evaluated the level of susceptibility of monocytes and lymphocytes to spontaneously induced and CH11-induced apoptosis in 16 patients with Brucella infection. The expression of some immunological and apoptotic markers was evaluated. Before therapy, monocytes showed a high level of resistance to spontaneously induced or CH11-induced apoptosis in all patients. In patients with acute infection, this resistance persisted for 10-20 days after treatment was initiated, then decreased; in chronically infected patients, it persisted after 45 days of treatment. Lymphocytes were also more resistant to CH 11-induced apoptosis. The level of activated CD8++ T lymphocytes was high in patients w…

Microbiology (medical)AdultAdolescentLymphocyteApoptosisBrucellaCD8-Positive T-LymphocytesMonocyteBrucellosisMonocytesBrucellosimedicineHumansLymphocytesfas ReceptorChildbiologybusiness.industryMonocyteAntibodies MonoclonalBrucellosisCD8-Positive T-LymphocyteT lymphocytebiology.organism_classificationmedicine.diseaseBrucellaInfectious Diseasesmedicine.anatomical_structureApoptosisChild PreschoolImmunologyAcute DiseaseChronic Diseasebiology.proteinLymphocyteAntibodybusinessCD8Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A pros…

2015

We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p < 0.0001).…

medicine.medical_specialtyCancer ResearchMultivariate analysisLymphomaChemotherapeutic approaches; Immunotherapy; Lymphoma and Hodgkin disease; Hematology; Oncology; Cancer ResearchMEDLINEDisease-Free SurvivalInternal medicineComprehensive Assesment Diffuse large B cell lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicine80 and overLarge B-CellHumansProspective StudiesProspective cohort studyGeriatric AssessmentAgedAged 80 and overChemotherapeutic approachesbusiness.industryPalliative CareGeriatric assessmentHematologymedicine.diseasePrognosisDiffuseSurgeryLymphomaSettore MED/15 - MALATTIE DEL SANGUETreatment OutcomeMulticenter studyOncologyLymphoma and Hodgkin diseaseMultivariate AnalysisTreatment decision makingImmunotherapyLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

2017

Thrombosis Risk factor
researchProduct

Familial essential thrombocythemia: 6 cases from a mono‐institutional series

2022

Rarely essential thrombocythemia (ET) is diagnosed in more than one person within a family. Familial myeloproliferative neoplasms are underdiagnosed. In this report, we describe 6 couples of familial ET, evaluating the heterogeneity of the mutational state and the clinical presentation.

essential thrombocythemia familial myeloproliferative neoplasmsGeneral MedicineClinical Case Reports
researchProduct

Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia

2019

Abstract The administration of cryopreserved platelets (PLTs) may overcome the limits of platelet shortage and availability, especially during some seasons or in specific contexts like rural areas. After in vitro validation studies, ad hoc prepared buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at -80 °C with a modified Valeri method, were transfused in patients with severe thrombocytopenia secondary to chemotherapy for acute leukaemia (AL). Five inpatients were enrolled in the pivotal clinical trial NCT02032134: 4 males and 1 female with a mean age of 71 years (range: 65–80). Four patients were diagnosed wi…

Blood PlateletsMalemedicine.medical_specialtymedicine.medical_treatmentPlatelet TransfusionBuffy coat030204 cardiovascular system & hematologyAcute leukaemiaCryopreservation03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPlateletAdverse effectAgedAged 80 and overCryopreservationChemotherapybusiness.industryTransfusionThrombinSevere thrombocytopeniaThrombosisHematologyCryopreserved plateletThrombocytopeniaSevere thrombocytopeniaClinical trialLeukemia Myeloid AcuteBlood PreservationConcomitantBlood Buffy CoatFemaleSafetybusiness030215 immunologyTransfusion and Apheresis Science
researchProduct

Immunosenescence and lymphomagenesis

2018

Abstract One of the most important determinants of aging-related changes is a complex biological process emerged recently and called “immunosenescence”. Immunosenescence refers to the inability of an aging immune system to produce an appropriate and effective response to challenge. This immune dysregulation may manifest as increased susceptibility to infection, cancer, autoimmune disease, and vaccine failure. At present, the relationship between immunosenescence and lymphoma in elderly patients is not defined in a satisfactory way. This review presents a brief overview of the interplay between aging, cancer and lymphoma, and the key topic of immunosenescence is addressed in the context of t…

lcsh:Immunologic diseases. AllergyAgingLymphomaImmunosenescenceImmunologyContext (language use)Diseaselcsh:Geriatricsmedicine.disease_cause03 medical and health sciences0302 clinical medicineImmune systemimmune system diseaseshemic and lymphatic diseasesmedicineCancerAutoimmune diseasebusiness.industryImmunosenescenceImmune dysregulationmedicine.diseaseLymphomagenesisEpstein–Barr virusLymphomaLymphomagenesiAgeinglcsh:RC952-954.6030220 oncology & carcinogenesisImmunologylcsh:RC581-607business030215 immunologyImmunity & Ageing
researchProduct

Synthesis and induction of G0–G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazep…

2007

The multistep synthesis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one 15 has been carried out. The compound showed antiproliferative and apoptotic effects against K562, K562-R (imatinib mesilate resistant), HL60 and multidrug resistant (MDR) HL60 cell lines. Compound 15 showed a pro-apoptotic activity against HL60 and K562 resistant cell lines markedly higher than etoposide and busulfan, respectively. Flow cytometry studies carried out on K562 cells allowed to establish that 15 induces G0-G1 phase arrest followed by apoptosis.

HL60StereochemistryApoptosisHL-60 CellsAntiproliferative activityResting Phase Cell CycleChemical synthesisPyrazolo[34-f][1234]tetrazepinoneFlow cytometrychemistry.chemical_compoundhemic and lymphatic diseasesDrug DiscoverymedicineHumansCytotoxicityEtoposideG0-G1 arrestPharmacologyTrifluoromethylMolecular Structuremedicine.diagnostic_testOrganic ChemistryG1 PhaseApoptosiAzepinesGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaMolecular biologyMultiple drug resistancechemistryApoptosisDrug resistancePyrazoles1234-TetrazepinoneK562 Cellsmedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate

2017

Key Clinical Message Prompt ophthalmology evaluation and immediate imatinib suspension should be suggested at any time of tyrosine kinase inhibitor therapy in patients with visual deficit, as it may be a clinical manifestation of optic disk edema, and suspension may help in prompt recovery.

Adverse event0301 basic medicinegenetic structuresmedicine.drug_classOptic Disk EdemaLate onsetCase ReportClinical manifestationCase ReportsTyrosine-kinase inhibitor03 medical and health sciences0302 clinical medicinechronic myeloid leukemiatyrosine kinase inhibitorsmedicineIn patientAdverse effectbusiness.industryoptic disk edemaImatinibGeneral Medicineeye diseases030104 developmental biologyImatinib mesylateimatiniboptic nerve edemaAnesthesiaAdverse events030221 ophthalmology & optometrybusinessmedicine.drugClinical Case Reports
researchProduct

Clinical utility and physician perceptions of a digital platform for electronic patient-reported outcomes monitoring in patients with hematologic mal…

2021

Abstract Background There is now great interest in using digital health tools to monitor patients' health status in real-world practice. Such tools often include electronic-patient-reported outcome (ePRO) systems in which symptoms questions are included into online interfaces for patient self-reporting, with real-time alerts triggered to the treating physician if severe symptoms or problems are reported. However, there is little information about the clinical utility and user perceptions of these systems, and this is particularly true in the area of hematology. Objectives This study investigates physicians' perceptions of usability and clinical utility of using remote ePROs in routine pract…

medicine.medical_specialtybusiness.industryFamily medicineImmunologyPhysician perceptionMedicineIn patientCell BiologyHematologybusinessBiochemistry
researchProduct

Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy

2022

B-cell lymphoma and lymphoproliferative diseases represent a heterogeneous and complex group of neoplasms that are accompanied by a broad range of immune regulatory disorder phenotypes. Clinical features of autoimmunity, hyperinflammation, immunodeficiency and infection can variously dominate, depending on the immune pathway most involved. Immunological imbalance can play a role in lymphomagenesis, also supporting the progression of the disease, while on the other hand, lymphoma acts on the immune system to weaken immunosurveillance and facilitate immunoevasion. Therefore, the modulation of immunity can have a profound effect on disease progression or resolution, which makes the immune syst…

immunosenescenceLymphoma B-CellimmunosuppressionLymphomaB-cell lymphomaOrganic ChemistryGeneral Medicineimmune recoverychemotherapytargeted therapyImmunotherapy AdoptiveLymphoproliferative DisordersCatalysisComputer Science ApplicationsCAR-TSettore MED/15 - Malattie Del SangueInorganic ChemistryImmune Systemimmune therapyTumor MicroenvironmentimmunoevasionHumansPhysical and Theoretical ChemistryMolecular BiologySpectroscopy
researchProduct

Cancer-Associated Deep Vein Thrombosis: The Role of Residual Vein Thrombosis for Assessing the Duration of Low Molecular Weight Heparin (the EXTENDED…

2014

Abstract Introduction. The optimal duration of Low Molecular Weight Heparin (LMWH) after cancer associated deep vein thrombosis (DVT) is unknown; current guidelines suggest to prolong anticoagulation until cancer is active. We have recently demonstrated, in a randomized trial, that detection of Residual Vein Thrombosis (RVT) after 6 months of LMWH identify patients who require or not extension of therapy with anticoagulants (JCO in press). Now we present data of a prospective study evaluating a RVT-based management of patients with cancer-associated DVT, in whom LMWH has been extended up to 2 years in patients considered at high-risk for recurrent DVT because of persistence of RVT. Material…

medicine.medical_specialtybusiness.industrymedicine.drug_classDeep veinImmunologyCancerLow molecular weight heparinCell BiologyHematologyHeparinmedicine.diseaseBiochemistryThrombosisGastroenterologylaw.inventionSurgerymedicine.anatomical_structureRandomized controlled triallawInternal medicineRelative riskmedicinebusinessProspective cohort studymedicine.drugBlood
researchProduct

HIV Infection in 403 Female Prostitutes in Italy

1991

Since the beginning of HIV epidemic, it became clear that the modality of transmission was different between Western Countries and Africa (1). Infact, in Africa heterosexual contact is the most important factor in the spread of HIV infection and female prostitutes are considered to be the major reservoir of HIVinfection (2).

business.industryTransmission (medicine)Hiv epidemicFemale prostituteHuman immunodeficiency virus (HIV)medicinemedicine.disease_causebusinessDemography
researchProduct

Paroxysmal nocturnal hemoglobinuria-like phenotype and thrombotic risk in several clinical disorders.

2021

Thrombotic riskCD55 Antigensbusiness.industryPNHHemoglobinuria ParoxysmalCD59 AntigensThrombosisGeneral Medicinemedicine.diseasePhenotypeSettore MED/15 - Malattie Del SanguePhenotypeImmunologyParoxysmal nocturnal hemoglobinuriaMedicineHumansParoxysmal nocturnal hemoglobinuriabusinessBiomarkersPanminerva medica
researchProduct

High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations.

2022

The high output heart failure is a clinical condition in which the systemic congestion is associated to a high output state, and it can be observed in a non-negligible percentage of hematological diseases, particularly in multiple myeloma, a condition in which the risk of adverse cardiovascular events may increase, with a worse prognosis for patients. For this reason, though an accurate literature search, we provided in this review a complete overview of different pathogenetic mechanisms responsible for high output heart failure in multiple myeloma. Indeed, this clinical finding is present in the 8% of multiple myeloma patients, and it may be caused by artero-venous shunts, enhanced angioge…

multiple myelomaangiogenesisCancer ResearchOncologyhyperammonemiahigh output heart failureNeoplasms. Tumors. Oncology. Including cancer and carcinogensangiogenesiglutamminolysiplasma viscosityglutamminolysisRC254-282artero-venous fistulaeCancers
researchProduct

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review

2021

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo wh…

0301 basic medicineOncologycardiovascular riskmedicine.medical_specialtychronic myelocytic leukemiacardio-oncologyPhysiologyReviewSettore MED/15 - Malattie Del Sangue03 medical and health sciencescardiovascular events0302 clinical medicineInternal medicinePhysiology (medical)hemic and lymphatic diseasesmedicineNeoplasmQP1-981Medical prescriptionAdverse effectMyeloproliferative neoplasmHematologyMechanism (biology)business.industryMyeloid leukemiamedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarerespiratory tract diseasestyrosine kinase inhibitions therapy030104 developmental biology030220 oncology & carcinogenesiscardiovascular events chronic myelocytic leukemia cardiovascular risk cardio-oncology tyrosine kinase inhibitions therapybusinessTyrosine kinaseFrontiers in Physiology
researchProduct

Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.

2019

The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and JAK2 V617F presence. The revised IPSET-thrombosis uses three adverse variables to delineate four risk categories: age greater than 60, thrombosis history, and JAK2 V617F presence. We compared different risk models in the estimation of thrombotic risk in 191 patients with ET and the role of specific driver mutations affecting overall survival, according to thrombotic risk. …

MaleCancer ResearchEssential Thrombocythemia Myeloproliferative Thrombosis Thrombotic risk SurvivalKaplan-Meier EstimateSeverity of Illness IndexSettore MED/15 - Malattie Del SanguePrognostic score0302 clinical medicineRisk groupsRecurrenceRisk FactorsMutational statusThrombophiliaAged 80 and overIncidenceAge FactorsHematologyGeneral MedicineMiddle AgedPrognosisThrombosisOncology030220 oncology & carcinogenesisFemaleJAK2 V617FReceptors ThrombopoietinThrombocythemia EssentialAdultPoor prognosismedicine.medical_specialtyAdolescentMutation MissenseModels BiologicalRisk Assessment03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAgedRetrospective StudiesThrombotic riskbusiness.industryEssential thrombocythemiaThrombosisJanus Kinase 2medicine.diseasebusinessCalreticulin030215 immunologyFollow-Up StudiesHematological oncologyREFERENCES
researchProduct

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone ly…

2015

Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%).…

MaleCancer ResearchBiopsymedicine.medical_treatmentfirst lineKaplan-Meier EstimateSplenic marginal zone lymphoma; first line; rituximabPolyethylene GlycolGastroenterologyPolyethylene GlycolsrituximabBone MarrowPrednisonefirst line; rituximab; splenic marginal zone lymphomaCause of DeathAntineoplastic Combined Chemotherapy ProtocolsSplenic marginal zone lymphomaAged 80 and overHematologyMiddle AgedPrognosisCombined Modality TherapySplenic NeoplasmTreatment OutcomeItalyOncologyVincristineFemaleRituximabHumanmedicine.drugAdultmedicine.medical_specialtyVincristineLymphoma B-CellCyclophosphamidePrognosiSplenectomySplenic NeoplasmNeutropeniaImmunophenotypingfirst line; rituximab; Splenic marginal zone lymphoma; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Italy; Kaplan-Meier Estimate; Lymphoma B-Cell; Male; Middle Aged; Polyethylene Glycols; Prednisone; Prognosis; Rituximab; Splenic Neoplasms; Treatment Outcome; Vincristine; Hematology; Oncology; Cancer ResearchInternal medicinemedicineHumansSplenic marginal zone lymphomaCyclophosphamideAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industrySplenic NeoplasmsBiomarkermedicine.diseaseSurgeryDoxorubicinPrednisonebusinessBiomarkers
researchProduct

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

2019

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.2 Myelofibrosis diagnosis relies upon the evaluation of several clinical and laboratory criteria suggested by the World Health Organization (WHO) in 2016.3 The major mutations leading to myelofibrosis usually occur in the JAK2, CALR, and MPL genes. However, in almost 10% of the cases, none of the above-mentioned mutations can be detected …

PharmacologyCytopeniamedicine.medical_specialtyRuxolitinibbusiness.industryIPSSruxolitinibprimary myelofibrosilcsh:RM1-950Case ReportGeneral Medicinemedicine.diseaseDiscontinuationPolycythemia veralcsh:Therapeutics. PharmacologyInternational Prognostic Scoring SystemInternal medicinemedicineprimary myelofibrosisMolecular MedicineMyelofibrosisAdverse effectbusinessMyeloproliferative neoplasmmedicine.drugDrugs in Context
researchProduct

Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antir…

2003

Aims: Highly active antiretroviral therapy (HAART) can induce an increase in lactic acid concentrations that seems to be caused by mitochondrial dysfunction induced by the interaction of nucleoside reverse transcriptase inhibitors (NRTIs) with DNA polymerase γ in the mitochondria. Mitochondrial alterations have been described in liver and muscle cells of NRTI treated human immunodeficiency virus (HIV) infected patients. Because lymphocytes are the main target for HIV and because mitochondria are involved in apoptosis, we studied mitochondrial morphology and apoptosis in the lymphocytes of an HIV infected patient with severe lactic acidosis after treatment with stavudine, didanosine, and ind…

Adultmedicine.medical_specialtyAnti-HIV AgentsLymphocyteApoptosisHIV InfectionsCase ReportsMitochondrionBiologyPathology and Forensic Medicinechemistry.chemical_compoundimmune system diseasesIndinavirAntiretroviral Therapy Highly ActiveInternal medicinemedicineHumansLymphocytesDidanosineAcridine orangeStavudinevirus diseasesGeneral Medicinemedicine.diseaseMitochondriaEndocrinologymedicine.anatomical_structurechemistryApoptosisLactic acidosisImmunologyAcidosis LacticFemalemedicine.drugJournal of Clinical Pathology
researchProduct

Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia

2022

Essential thrombocythemia, as defined by the WHO in 2016, is a Philadelphia-negative chronic myeloproliferative neoplasm showing a better prognosis than polycythemia vera and myelofibrosis. In a variable percentage, patients with essential thrombocythemia show none of the known driver-gene mutations that may occur on JAK2, CALR, and MPL genes. Such patients are classified as triple-negative and their clinical features and prognosis have not been described with precision yet. In this study, we evaluated some of the characteristics of this population by comparing them with those of patients with driver-gene mutated ET. Data from 266 consecutive essential thrombocythemia patients were analysed…

essential thrombocythemia survival triple-negative triple-negativityHematology
researchProduct

Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents

2021

Thrombosis and neoplasms are strictly linked, and the diagnosis of a malignancy is a relevant risk factor for venous thromboembolism (VTE). In particular, between gammopathies, the VTE risk is known to be increased in both monoclonal gammopathy of uncertain significance and in multiple myeloma, with a 3- and 9-fold increase respectively, when compared to the general population. The risk appears to be further increased in patients treated with immunomodulating drugs, such as thalidomide, especially when in combination with dexamethasone or conventional cytotoxic chemotherapies, and lenalidomide. In 2008 the International Myeloma Working Group put out thrombosis prophylaxis recommendations fo…

medicine.medical_specialtyPopulationAntineoplastic Agents030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicinemedicineHumansImmunologic FactorsRisk factoreducationMultiple myelomaLenalidomideeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismGeneral MedicineEvidence-based medicinemedicine.diseaseThrombosisPrevention and controlThalidomideTreatment OutcomeMultiple MyelomabusinessProteasome Inhibitorsmedicine.drugPanminerva Medica
researchProduct

Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype

2020

The complement system is an essential component of the innate immune defence that, if overly activated, may damage organs and tissues. For this reason, there is a fine complement regulatory system. The complement modulation system includes two proteins with important regulatory activity, CD55 or decay accelerating factor (DAF) and CD59 or membrane inhibitor of reactive lysis (MIRL). The paroxysmal nocturnal hemoglobinuria (PNH) is a clonal and non-neoplastic disease characterized by intravascular haemolysis, occurrence of thrombosis and bone marrow failure. In clinical practice, in opposition to PNH, a variety of pathological conditions have been observed with an acquired and non-genetic de…

PhysiologyHemoglobinuria ParoxysmalDiseaseCD59030204 cardiovascular system & hematologyHemolysis030218 nuclear medicine & medical imagingSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesPhysiology (medical)medicineHumansParoxysmal nocturnal hemoglobinuriaDecay-accelerating factorcomplement systemInnate immune systembusiness.industryThrombosisHematologythromboembolic riskmedicine.diseasePhenotypeComplement systemPhenotypemedicine.anatomical_structureImmunologyParoxysmal nocturnal hemoglobinuriaBone marrowCD55Cardiology and Cardiovascular MedicinebusinessCD59
researchProduct

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

2019

Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to promoting the thrombotic event due to the interaction between platelets, leukocytes, and endothelium alterations. Moreover, a significant role can be played by cardiovascular risk factors (CV.R) such as cigarette smoking habits, hypertension, diabetes, obesity and dyslipidemia. In this study, we evaluated the impact that CV.R plays on thrombotic risk and survival in patients with PV and ET .

medicine.medical_specialtyEndotheliumGastroenterologySettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicinePolycythemia veraInternal medicineDiabetes mellitushemic and lymphatic diseasesmedicinePlateletEssential ThrombocythemiaPolycythemia VeraThrombotic riskEssential thrombocythemiabusiness.industrylcsh:RC633-647.5Hematologylcsh:Diseases of the blood and blood-forming organsmedicine.diseaseObesityPolycythemia vera Essential ThrombocytemiaInfectious Diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisOriginal ArticlebusinessDyslipidemia030215 immunologyMediterranean Journal of Hematology and Infectious Diseases
researchProduct

The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors

2020

Essential thrombocythemia is a rare hematological malignancy with good overall survival, but moderate to high risk of developing arterial or venous thrombosis lifelong. Different thrombotic risk scores for patients with essential thrombocythemia have been proposed, but only one of them (the IPSET-t scoring system) takes into account the classical cardiovascular risk factors as one of the scoring items. Currently, in clinical practice, the presence of cardiovascular risk factors in patients with diagnosis of ET rarely determines the decision to initiate cytoreductive therapies. In our study, we compared different risk models to estimate the thrombotic risk of 233 ET patients and the role of …

Thrombotic riskmedicine.medical_specialtyArticle SubjectEssential thrombocythemiabusiness.industryCardiovascular risk factorsMEDLINEHematologymedicine.diseaseThrombosisObesitySettore MED/15 - Malattie Del Sangue03 medical and health sciencesVenous thrombosis0302 clinical medicine030220 oncology & carcinogenesisDiabetes mellitusmedicineDiseases of the blood and blood-forming organsRC633-647.5Intensive care medicinebusinesspolycythemia vera essential thrombocytemia030215 immunologyResearch ArticleAdvances in Hematology
researchProduct

Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma

2019

Background: CD8+ T cell responses are an essential component of the adaptive immune system. After resolution of infection a small population of memory cells is formed. In relation to circulatory patterns, different subsets of memory CD8+ T cells can be identified: the central memory (CM) and the effector memory T cells (EM) (Martin MD, et al., Front Immunol. 2018). In addition, it has been described a subset of resident memory T cells (TRM) permanently living in peripheral tissues, including the bone marrow (BM) (Di Rosa F., et al., Nat Rev Immunol. 2016). It is conceivable that these cells can contribute to the defence toward haematological tumours infiltrating the BM. Therefore, we perfor…

education.field_of_studymedicine.medical_treatmentT cellCD3ImmunologyPopulationCell BiologyHematologyBiologyBiochemistryMolecular biologySettore MED/15 - Malattie Del SangueCytokinemedicine.anatomical_structurebone marrow multiple myeloma t-lymphocytes memory cytokine interleukin-15 interleukin-7 cd45 antigens immunoglobulin a immunoglobulin g ki-67 antigenInterleukin 15medicinebiology.proteinCytotoxic T cellBone marroweducationCD8Blood
researchProduct

Functional In Vitro Studies Of Buffy Coat Pooled Platelets Cryopreserved In Dimethyl-Sulphoxide With a New System

2013

Abstract Introduction Cryopreservation for long term storage of platelets (PLTs) represents a clinical useful method for avoiding platelet shortage. Many studies have tried to define, in vitro and in vivo, the entity and weight of storage-related PLTs lesions with discordant results related to different methods. We have performed an in vitro prospective study to evaluate PLTs count, viability and function of buffy coat derived pooled platelet concentrates (BC-PLTs) treated with dimethyl-sulphoxide (DMSO) and cryopreserved at -80°C with an innovative patented system not requiring laminal flow hoods and external manipulations. Materials and methods Each BC-PLTs was obtained from 5 buffy coats…

medicine.diagnostic_testCryopreserved platelets DMSOImmunologyCell BiologyHematologyBuffy coatBiologyBiochemistryThromboelastographyCryopreservationAndrologyIn vivoHemostasisImmunologymedicinePlateletMean platelet volumeAnnexin A5
researchProduct

ChemInform Abstract: Synthesis and Induction of G0-G1 Phase Arrest with Apoptosis of 3,5-Dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,…

2009

The multistep synthesis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one 15 has been carried out. The compound showed antiproliferative and apoptotic effects against K562, K562-R (imatinib mesilate resistant), HL60 and multidrug resistant (MDR) HL60 cell lines. Compound 15 showed a pro-apoptotic activity against HL60 and K562 resistant cell lines markedly higher than etoposide and busulfan, respectively. Flow cytometry studies carried out on K562 cells allowed to establish that 15 induces G0-G1 phase arrest followed by apoptosis.

Trifluoromethylmedicine.diagnostic_testHL60General MedicineMolecular biologyFlow cytometryMultiple drug resistancechemistry.chemical_compoundchemistryApoptosishemic and lymphatic diseasesmedicineBusulfanEtoposidemedicine.drugK562 cellsChemInform
researchProduct

Paroxysmal nocturnal haemoglobinuria: When delay in diagnosis and long therapy occurs

2017

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, caused by a somaticmutation in PIG-A gene that results in theabsence of CD55 and CD59, two important complement regulatory proteins. In thispaper, a case of PNH is retrospectively examined looking for clinical and laboratory features, and the entire course of the disease from the onset of the symptoms isdescribed, together with an adequate follow-up over a 7-years treatment period. Inthis case, the not specificity and the limited clinical relevance of the symptoms led to adelay in diagnosis. After thrombosis, Eculizumab therapy has been shown to be effec…

0301 basic medicineHemolytic anemiaPediatricsmedicine.medical_specialtyrenal failureParoxysmal nocturnal haemoglobinuriaparoxysmal nocturnal hemoglobinuriaCase ReportDiseaseCD5903 medical and health sciencesthrombotic eventshemic and lymphatic diseasesMedicineClinical significancebusiness.industrylcsh:RC633-647.5Bone marrow failureHematologylcsh:Diseases of the blood and blood-forming organsEculizumabEculizumabmedicine.diseaseThrombosisparoxysmal nocturnal hemoglo-binuria thrombotic events renal failure Eculizumab030104 developmental biologyParoxysmal nocturnal hemoglobinuriabusinessmedicine.drug
researchProduct

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

2018

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revis…

BendamustineAdultMalemedicine.medical_specialtyPhases of clinical researchNeutropeniaGastroenterologyDisease-Free SurvivalDrug Administration ScheduleSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicineInternal medicinefirst-line therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineBendamustine HydrochlorideHumansSplenic marginal zone lymphomabendamustineAgedbusiness.industrySplenic NeoplasmsHematologyLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseLymphomaimmunochemotherapyRegimenTreatment Outcome030220 oncology & carcinogenesisbendamustine; first-line therapy; immunochemotherapy; rituximab; Splenic Marginal Zone Lymphoma; HematologySplenectomyRituximabFemaleSplenic Marginal Zone LymphomaNeoplasm Recurrence LocalbusinessRituximabFebrile neutropenia030215 immunologymedicine.drugBritish journal of haematology
researchProduct

Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association

2019

Von Willebrand disease (VWD) is the most common inherited bleeding disorder and is caused by a quantitative (type 1 and 3) or qualitative (type 2) defect of Von Willebrand factor (VWF). Bleeding from the gastrointestinal (GI) tract is not uncommon in VWD and is usually associated with angiodysplasia. We report herein on the management of a patient affected by VWD2B with severe GI bleeding secondary to gastrointestinal stromal tumor (GIST) complicated by deep vein thrombosis (DVT). The current case demonstrated that the hemostatic balance, in RBDs under specific circumstances, can range from a tendency toward a hemorrhagic to normal or prothrombotic state. In these patients, a close collabor…

medicine.medical_specialtyGastrointestinal bleedingGastrointestinal Stromal TumorsDeep veinGastrointestinal stromal tumor (GIST)030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseasesInternal medicinemedicineVon Willebrand diseaseHumansAngiodysplasiaStromal tumorGastrointestinal bleedingGiSTbiologybusiness.industryHematologyMiddle Agedmedicine.diseaseThrombosisvon Willebrand DiseasesThrombotic riskmedicine.anatomical_structurebiology.proteinFemalebusinessVon Willebrand 2B030215 immunology
researchProduct

Plasma HIV-1 RNA and route of transmission in oral candidiasis and oral hairy leukoplakia

2000

AdultMaleOral hairy leukoplakiaLeukoplakia HairyAIDS-Related Opportunistic InfectionsTransmission (medicine)business.industryHIV InfectionsHomosexualityViral LoadVirologyHiv 1 rnaCD4 Lymphocyte CountOtorhinolaryngologyCandidiasis OralHIV-1HumansRNA ViralMedicineBlood TransfusionFemaleHeterosexualitySubstance Abuse IntravenousbusinessGeneral DentistryOral Diseases
researchProduct

Erythrocyte deformability profile evaluated by laser diffractometry in patients with multiple myeloma: Re-examination of our cases.

2023

Background: Multiple myeloma is a complex pathology which represents about 10 % of all hematological neo-plasms. It can often present changes in the hemorheological profile and, in relation to this last topic, our aim is to evaluate the hemorheological profile in a group of multiple myeloma patients, with reference to erythrocyte deformability. Methods: We have examined the profile of the erythrocyte deformability in multiple myeloma enrolling 29 pa-tients; this profile, expressed as elongation index at several shear stress, has been obtained using the diffracto-metric method. Results: By comparing normal controls and MM patients, a significant decrease in erythrocyte deformability, especia…

MicrocirculationErythrocyte deformabilityMultiple myeloma.Cell BiologyCardiology and Cardiovascular MedicineHemorheological profileBiochemistryMicrovascular research
researchProduct

Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study

2014

Purpose We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients and Methods Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after disconinuation of LMWH, and the secondar…

Cancer Researchmedicine.medical_specialtymedicine.drug_classDeep veinPopulationLow molecular weight heparinSettore MED/42 - Igiene Generale E ApplicataGroup BSettore MED/15 - Malattie Del SangueInternal medicineresidual vein thrombosis low molecular weight heparin cancer patientsmedicineeducationFirst episodeeducation.field_of_studybusiness.industrylow molecular weight heparinHazard ratioantivitamin K; low molecular weight heparin; nadroparinCancermedicine.diseaseThrombosisSurgerymedicine.anatomical_structureOncologynadroparinantivitamin Kbusiness
researchProduct

<p>Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study</p>

2020

Purpose Insufficient knowledge of primary immune thrombocytopenia purpura (ITP) in the elderly, together with a lack of clinical trial data, has resulted in wide variation in treatments. Here, we present a study focused on clinical characteristics of ITP in older subjects at diagnosis integrated with the subsequent course of the disease and treatment history. Methods In a retrospective monoinstitutional study, we evaluated >65-year-old patients with primary ITP. Clinical characteristics at the time of diagnosis were described and analyzed. We aimed to delineate whether subsequent lines of therapy influenced the number of relapses. In addition to initial regimens, we reported subsequent trea…

Severe bleedingmedicine.medical_specialtybusiness.industryRetrospective cohort studyHematologyDisease030204 cardiovascular system & hematologyImmune thrombocytopeniaClinical trial03 medical and health sciencesPurpura0302 clinical medicine030220 oncology & carcinogenesisStatistical significanceInternal medicineMedicinemedicine.symptombusinessClinical phenotypeJournal of Blood Medicine
researchProduct

Gender differences in human immunodeficiency virus–related oral lesions: An Italian study

2001

Abstract Objective: The purpose of this study was to investigate the relationship between oral lesions and gender, age, CD4+ cell count, human immunodeficiency virus-1 (HIV-1) viral load, antiretroviral therapy, and route of transmission in a group of HIV-infected (HIV+) persons from the Mediterranean region. Study Design: The participants in this study were HIV+ adults who sought dental care between January 1999 and June 1999 in the Department of Oral Medicine (University of Palermo, Italy). Results: One hundred thirty-six HIV+ adults came in for an initial oral examination. Their mean age was 35.2 years (SD ± 7.97), and 33% were women. Their mean CD4+ cell count was 325.3 × 106 /L (SD ± 2…

AdultMalemedicine.medical_specialtyStatistics as TopicHIV InfectionsAntiviral AgentsStatistics NonparametricSex FactorsAcquired immunodeficiency syndrome (AIDS)Candidiasis OralInternal medicineImmunopathologyOral and maxillofacial pathologyEpidemiologyPrevalenceHumansMedicineSidaSicilyGeneral DentistryAnalysis of VarianceChi-Square DistributionAIDS-Related Opportunistic Infectionsbiologybusiness.industryAge FactorsViral Loadmedicine.diseasebiology.organism_classificationCD4 Lymphocyte Countstomatognathic diseasesItalyOtorhinolaryngologyImmunologyHIV-1FemaleSurgeryViral diseaseOral SurgeryMouth DiseasesbusinessViral loadOral medicineOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology
researchProduct

Candidal carriage in the oral cavity of human immunodeficiency virus–infected subjects

2002

Abstract Objectives. We sought to assess asymptomatic oral carriage of Candida species and relative density in human immunodeficiency virus-infected (HIV+) subjects, as well as to determine whether yeast carriage is associated with CD4+cell count, HIV-1 RNA quantity, gender, route of HIV transmission, antiretroviral therapy, or smoking. Study Design. A cross-sectional analysis of oral rinses from HIV+ and healthy subjects was undertaken. Oral candidal carriage and relative species were investigated in 42 HIV+ and 41 healthy individuals, all of whom were seen at the Palermo University Department of Oral Sciences, Italy. Data were managed and analyzed by means of the computer software package…

AdultMalemedicine.medical_specialtyColony Count MicrobialAsymptomaticStatistics NonparametricAcquired immunodeficiency syndrome (AIDS)Candidiasis OralInternal medicineHumansMedicineMycological Typing TechniquesSidaCandida albicansGeneral DentistryMycosisCandidaMouthChi-Square DistributionAIDS-Related Opportunistic Infectionsbiologybusiness.industryMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseCD4 Lymphocyte CountCross-Sectional StudiesCarriageOtorhinolaryngologyOral microbiologyCarrier StateImmunologyHIV-1FemaleSurgeryOral Surgerymedicine.symptombusinessViral loadOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology
researchProduct

Detection of a new 3-base pair insertion mutation in the protease gene of human immunodeficiency virus type 1 during highly active antiretroviral the…

2005

To investigate a new insertion mutation in the protease (PR) gene of human immunodeficiency virus type 1 (HIV-1) in a patient extensively pretreated with antiretroviral drugs, genotypic analyses of plasma-derived viruses were performed by sequencing segments of 1302 nucleotides in the pol gene of HIV-1. Despite optimal compliance to highly active antiretroviral therapy (HAART) the patient showed poor virological success. Nucleotide sequences of retrospective available plasma samples exhibited a previously unknown 3-bp insertion mutation, corresponding to a leucine, between codons 31 and 32 of the PR gene. This kind of mutation appears to be very rare and it does not seem to be associated wi…

AdultSequence analysismedicine.medical_treatmentImmunologyMolecular Sequence DataGene Products polHIV InfectionsVirusHIV ProteaseVirologyAntiretroviral Therapy Highly ActivemedicineHumansInsertionCodonGeneBase PairingGeneticsProteasebiologyBase SequenceSequence Analysis DNAbiology.organism_classificationVirologyInfectious DiseasesLentivirusMutation (genetic algorithm)MutationHIV-1FemaleViral diseaseAIDS research and human retroviruses
researchProduct

Presence of Epstein-Barr virus, cytomegalovirus and human papillomavirus in normal oral mucosa of HIV-infected and renal transplant patients

2001

OBJECTIVES: To determine the prevalence of EBV-DNA,CMV-DNA and HPV-DNA in oral healthy mucosa of HIV-infected and renal transplant patients. To associate the detection of viral genomes with laboratory parameters of immunodeficiency, gender, antiretroviral and immunosuppressive therapy. DESIGN: A cross-sectional analysis of lingual and buccal cytobrushings from HIV-infected and renal transplant patients. SUBJECTS AND METHODS: Lingual and buccal cytobrushings were obtained from clinically normal oral mucosa of 57 HIV+, 40 renal transplant patients and 30 healthy uninfected controls, all matched for age at baseline of examination. Presence of EBV-, CMV- and HPV-DNA was assessed by polymerase c…

Human cytomegalovirusKidneybiologybusiness.industryvirus diseasesmedicine.diseasebiology.organism_classificationmedicine.disease_causeHerpesviridaeTransplantationmedicine.anatomical_structureOtorhinolaryngologyAcquired immunodeficiency syndrome (AIDS)ImmunologyLentivirusmedicineViral diseasebusinessGeneral DentistryImmunodeficiencyOral Diseases
researchProduct

Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Ve…

2019

<b><i>Background/Aims:</i></b> Cardiovascular risk factors are not considered in the current scores for evaluation of the thrombotic risk in myeloproliferative neoplasms, and in polycythemia vera (PV) in particular. Cytoreduction is currently not indicated in low-risk patients with PV, despite the absence or presence of cardiovascular risk factors. Our purpose is to highlight how cardiovascular risk factors in patients with PV increase the thrombotic risk both in low- and high-risk patients. <b><i>Methods:</i></b> We collected and analyzed data from 165 consecutive patients with a diagnosis of PV followed at our institution and compared the fr…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationCardiovascular risk factorsKaplan-Meier EstimateSettore MED/15 - Malattie Del SangueCytoreductionYoung AdultPolycythemia veraSurvival dataInternal medicinemedicineHumansIn patienteducationAgedRetrospective StudiesAged 80 and overThrombotic riskeducation.field_of_studybusiness.industryThrombosisCytoreduction Surgical ProceduresHematologyMiddle AgedCardiovascular riskmedicine.diseaseThrombosisPolycythemia veraOncologyCardiovascular DiseasesHeart Disease Risk FactorsRisk stratificationFemalebusinessOncology Research and Treatment
researchProduct

Long Term Results of Stanford V Regimen and Highly Active Antiretroviral Therapy (HAART) In 59 Patients (pts) with HD and HIV Infection (HD-HIV)

2010

Abstract Abstract 4827 Background: The introduction of HAART has significantly improved the outcome of pts with HD-HIV. However there are no data on the long term follow-up of HD-HIV pts treated with conventional chemotherapy (CT) regimens. In 2002, we reported the results of a prospective phase II study with the intensive 12-week CT with adjuvant radiotherapy (Stanford V) and concomitant HAART in 59 pts (Spina et al. Blood 2002;100:1984-1988). Methods: To analyze the long term outcome of patients included in the Stanford V and HAART protocol. Results: The median follow-up is 67months (range 3–156 months The 5-yr overall survival (OS), freedom from progression (FFP), disease free survival a…

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyHuman immunodeficiency virus (HIV)Phases of clinical researchCell BiologyHematologyStanford V regimenLong term resultschemotherapymedicine.disease_causemedicine.diseaseBiochemistrySettore MED/15 - Malattie Del SangueSurgeryStanford VIdiopathic pneumonia syndromeInternal medicineConcomitantmedicineHodgkin's diseaseFresh frozen plasmabusinessBlood
researchProduct

Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma

2022

Assessment of host-related factors is a crucial aspect in the comprehensive management of cancer patients. A distinct nutritional disturbance linked to cancer has been recognized to be associated with negative outcomes. However, compared to solid tumors, only a limited number of studies have looked specifically at nutritional issues in the field of lymphoma. The aim of this review is to integrate the current knowledge on interactions between malnutrition and lymphoma and address most relevant and pertinent questions. We first provide a literature review on the mutual biological relationship between malnutrition and lymphoma. Next, we explore the overlap between malnutrition, sarcopenia, cac…

Cancer ResearchSarcopeniaCachexiaFrailtyLymphoma Non-Hodgkinnon-Hodgkin lymphomaMalnutritionHematologyGeneral MedicineDiffuse large B-cell lymphomaOncologyNutritional statusNeoplasmsHumansCancer metabolic syndrome
researchProduct

Antimicorbial prophylaxis in patients with immune thrombocytopenia treated with rituximab:a retrospective analysis

2019

anticmirbial prophylaxisimmune thrombocytopeniaanti-CD20 immunesuppressive therapy
researchProduct

Antibodies to human herpes virus type 8 (HHV8) in general population and in individuals at risk for sexually transmitted diseases in Western Sicily.

2000

Human herpes virus 8 (HHV8) appears to be the primary aetiologic agent of Kaposi sarcoma (KS). To study the distribution of HHV8, a seroepidemiological study was carried out in western Sicily, where a high incidence rate of classical KS is well documented.A total of 970 sera of healthy human immunodeficiency virus (HIV) negative individuals of general population (1-70 years old) and 742 sera of individuals in different risk groups for HIV infection were evaluated by means of an indirect immunofluorescence assay able to detect antibodies to lytic and latent HHV8 antigens.Crude seroprevalence to HHV8 antigens was 11.5% in the general population, and it increased significantly with age from 6%…

Sexually transmitted diseaseAdultMalemedicine.medical_specialtyAdolescentEpidemiologyPopulationSexually Transmitted DiseasesHIV InfectionsSerologyRisk FactorsSeroepidemiologic StudiesEpidemiologyMedicineSeroprevalenceHumansRisk factorHomosexuality MaleeducationChildSubstance Abuse IntravenousSarcoma KaposiSicilyAgededucation.field_of_studybusiness.industryTransmission (medicine)InfantGeneral MedicineHerpesviridae InfectionsMiddle AgedSex WorkHeterosexualityChild PreschoolImmunologyHerpesvirus 8 HumanFemalebusinessDemographyInternational journal of epidemiology
researchProduct

Acquired haemophilia in cancer: A systematic and critical literature review

2017

Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and fe…

medicine.medical_specialtyContext (language use)Antineoplastic AgentsFactor VIIa030204 cardiovascular system & hematologyMalignancyHemophilia AGastroenterology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsAcquired haemophiliamedicineHumanscancerhaematological malignancyGenetics (clinical)Blood Coagulation Factor Inhibitorstreatmentbusiness.industryIncidence (epidemiology)AutoantibodyCancerHematologyGeneral Medicinemedicine.diseasebleedingBlood Coagulation FactorsRecombinant ProteinsSurgeryinhibitordiagnosiSystematic reviewTreatment Outcome030220 oncology & carcinogenesisHematologic Neoplasmsacquired haemophilabusinessHaematological malignancy
researchProduct

Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors

2019

Cardiovascular (CV) adverse events are considered common complications of ponatinib treatment. Recently, it has been demonstrated that ponatinib dose reductions in definite settings can obtain optimal responses and lower ponatinib-related CV events. In this study, we describe the management of 5 patients with chronic myeloid leukemia treated with ponatinib, from second to fourth line of tyrosine kinase inhibitor therapy, carrying high pre-ponatinib CV risk, who obtained optimal molecular response and developed no CV adverse event during follow-up. Among these 5 patients, 2 had diagnosis of ischemic heart disease and underwent percutaneous angioplasty, 2 had type 2 diabetes and arterial hype…

0301 basic medicinemedicine.medical_specialtymedicine.drug_class030106 microbiologyCardiovascular risk factorsType 2 diabetesDiseaseTyrosine-kinase inhibitorSettore MED/15 - Malattie Del Sangue03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoverymedicinePharmacology (medical)In patientAdverse effectPharmacologybusiness.industryPonatinibChronic myeloid leukemiaMyeloid leukemiaGeneral Medicinemedicine.diseaseCardiovascular riskInfectious DiseasesOncologychemistry030220 oncology & carcinogenesisPonatinibbusiness
researchProduct

Bendamustin in association with Rituximab (BR) in the treatment of patients with relapsed/refractory lymphoid neoplasm. A GISL retrospective study

2009

Lymphoid neoplasms bendamustinSettore MED/15 - Malattie Del Sangue
researchProduct

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

2014

Antiviral Treatment indolent B cell lymphomaHCv infection
researchProduct

PREDICTORS OF RESIDUAL VEIN THROMBOSIS AFTER CANCER-RELATED DEEP VEIN THROMBOSIS OF THE LOWER LIMBS

2012

Thrombosicancer
researchProduct

A Case of Fatal Drug Rash Eosinophilia and Systemic Symptoms from Allopurinol

2015

Hypereosinophilia is a systemic condition that has several possible etiologies: allergies, medications, infectious, autoimmune or other systemic diseases, and finally idiopathic forms. Skin involvement seems to relate to subcutaneous inflammatory infiltration in this condition, as can be observed in parasitic, autoimmune and bullous diseases, as well as in drug reactions. Generalizing, a severe adverse drug-induced reaction may cause a systemic inflammatory disease: Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). Its diagnosis requires the application of a complex diagnostic algorithm and immediate identification to prevent inauspicious evolution. The prognosis is severe; drug di…

Settore MED/09 - Medicina Internadress syndrome allopurinol
researchProduct

Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study

2020

Salvatrice Mancuso,1 Melania Carlisi,1 Nicola Serra,2,3 Mariasanta Napolitano,1 Simona Raso,3 Ugo Consoli,4 Roberto Palazzolo,5 Maria Rosa Lanza Cariccio,6 Sergio Siragusa1 1Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, Palermo, Italy; 2Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy; 3Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy; 4UOC Ematologia ARNAS Garibaldi, Catania, Italy; 5UOS Ematologia, Asst Valtellina e Alto Lario, Sondrio, Italy; 6Dipartimento Oncologico, La Maddalena,…

immunogeriatricsaging.immuno-geriatricsitp treatmentlcsh:RC633-647.5agingImmunogeriatriclcsh:Diseases of the blood and blood-forming organsSettore MED/15 - Malattie Del SangueJournal of Blood Medicinetpo-receptor agonistprimary immune thrombocytopenia (itp)ITPPrimary immune thrombocytopeniaOriginal ResearchJournal of Blood Medicine
researchProduct

Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials

2023

The treatment of chronic lymphocytic leukemia (CLL) currently relies on the use of chemo-immunotherapy, Bruton’s tyrosine kinase inhibitors, or BCL2 inhibitors alone or combined with an anti-CD20 monoclonal antibody. However, the availability of multiple choices for the first-line setting and a lack of direct head-to-head comparisons pose a challenge for treatment selection. To overcome these limitations, we performed a systematic review and a network meta-analysis on published randomized clinical trials performed in the first-line treatment setting of CLL. For each study, we retrieved data on progression-free survival (according to del17/P53 and IGHV status), overall response rate, complet…

network metanalysiBruton’s tyrosine kinase inhibitorschronic lymphocitic leukemiaCLL
researchProduct

Screening sierologico per Leishmania infantum su donatori di sangue e HIV+ asintomatici residenti in area endemica [Serological screening for Leishma…

2008

Visceral leishmaniasis (VL) is endemic in Sicily (48 new cases in 2004, of which nine were in Agrigento). In southern Europe between 25-70 per cent of adult VL cases are related to HIV infection. The HIV cases have a high risk (1.5-9%) of developing VL either as a new infection or as the revival of a latent infection. We therefore carried out serologic screening to detect antibodies against L. infantum by IFAT in 1449 blood donors in Agrigento and the surrounding area (May-December 2005) and in 120 HIV+ in western Sicily, all of whom were asymptomatic and had no history of VL. L. DNA was assessed by nested PCR in blood samples of some seropositive donors. Of the 1449 blood donors, 11 (0.75%…

Blood donors Coinfection HIV LeishmaniasisSettore MED/15 - Malattie Del Sangue
researchProduct

ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. FINAL RESULTS OF A MULTICENTER S…

2012

multiple myeoloma lymphocite count prognostic factorsSettore MED/15 - Malattie Del Sangue
researchProduct

CANCER AS A PREDICTOR FOR INCREASED PERIPROCEDURAL BLEEDING DURING SURGERY OR PLATELET-INDUCED CHEMOTHERAPY IN CHRONICALLY ANTICOAGULATED PATIENTS

2012

Anticoagulation bleedingSettore MED/15 - Malattie Del Sangue
researchProduct

Molecular epidemiology of HIV type 1 (HIV-1) non-B subtypes in SIcily

2004

HIV-1non-B subtypeSettore MED/42 - Igiene Generale E ApplicataSicily
researchProduct

INFEZIONE DA HIV E IMMIGRATI NEGLI ULTIMI CINQUE ANNI DI ATTIVITA' DEL NOSTRO CENTRO

2006

researchProduct

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

2012

Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the ma…

MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusiness
researchProduct

Prevalence of Giardia, Cryptosporidium and Isospora in HIv-seropositive individuals in Sicily.

2004

researchProduct

ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

2012

multiple myelomalymphocyte count
researchProduct

VALIDITA' DEL METODO DI IMMUNOFLUORESCENZA DIRETTA NELLA DIAGNOSI DI GIARDIASI IN UN SOGGETTO HIV+

2006

researchProduct

Screening sierologico per l'infantum in soggetti HIV+ in area endemica Sicilia occidentale

2006

researchProduct

Clinical history of thrombosis before diagnosis of overt myeloproliferative neoplasms in triple negative patients

2017

Thromboses are the most important preventable risk factors for morbidity and mortality in myeloproliferative neoplasms (MPN). We here performed a retrospective cross sectional study of patients with a diagnosis of Philadelphia negative MPN and a prior history of thrombosis, analyzed from electronic charts. Among a cohort of 260 patients with MPNs (78PV, 102ET, 80 MF), forty four were found triple negative for JAK-2, calreticulin and MPL gene mutations. Sixty-nine (26.54%) patients (29F, 40M) had a personal past clinical history of arterial or venous thrombosis. Among patients with thrombosis, 13(18.8%) cases (11ET, 2MF) were triple negative (median age:60 years). Most events, in particular …

chronic Myeloproliferative neoplasmchronic Myeloproliferative neoplasms; ThrombosisThrombosis
researchProduct

Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study

2009

chronic myeloid leukemia secondary malignancySettore MED/15 - Malattie Del Sangue
researchProduct

Dimagrimento e diarrea: oltre la "wasting syndrome"

2007

researchProduct

Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review.

2012

MaleMutationHemoglobinuria ParoxysmalHumansMembrane ProteinsFemaleThrombosisReviewEPNSettore MED/15 - Malattie Del Sangue
researchProduct

BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS SALVAGE THERAPY FOR SPLENIC MARGINAL ZONE LYMPHOMA

2010

At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy is still deemed to be the best choice for patients requiring treatment. Nevertheless, the high fraction of patients achieving a clinical response following splenectomy eventually relapses or progresses

splenic marginal zone lymphomabendamustineSettore MED/15 - Malattie Del Sangue
researchProduct

Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-trifluoromethyl-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin…

2007

researchProduct

Lymphonodal amyloidosis: case report

2009

Amyloidosis lymphomaSettore MED/15 - Malattie Del Sangue
researchProduct

VEBEP REGIMEN IN PATIENTS (PTS) WITH HD AND HIV INFECTION(HD-HIV): FINAL RESULTS OF A PHASE II STUDY OF THE ITALIAN COOPERATIVE GROUP ON AIDS AND TUM…

2011

chemotherapyHIV infectionHodgkin' disease
researchProduct

DETECTION OF HIV TYPE 1 (HIV-1) NON-B SUBTYPES IN SICILY, ITALY

2004

To evaluate the presence of HIV-1 non-B subtypes in Sicily, we sequenced and genotyped HIV-1 PR and RT regions of the pol gene using plasma from 169 HIV-1-infected adult patients. All samples were obtained from a study of antiretroviral-associated resistance mutations resulting in virological failure during highly active antiretroviral therapy (HAART). Eight (4.7%) patients had the non-B HIV-1 subtype including some circulating recombinant forms (CRFs). All of these individuals acquired the infection by heterosexual transmission. The detection of HIV-1 non-B strains was significantly associated with younger age of HIV-1 acquisition. Our findings indicate, for the first time, the presence of…

ItalyHIV-1non-B subtypeSettore MED/42 - Igiene Generale E ApplicataSicily
researchProduct

ABSOLUTE LYMPHOCYTE COUNT AS PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

2011

multiple myelomaSettore MED/15 - Malattie Del Sangue
researchProduct

Chronic myeloid leukemia as second malignancy; restrospective multicentric study

2009

chronic myeloid leukemia second malignancySettore MED/15 - Malattie Del Sangue
researchProduct

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-co…

2008

Background: Whether nucleoside reverse transcriptase inhibitors increase the risk of myocardial infarction in HIV-infected individuals is unclear. Our aim was to explore whether exposure to such drugs was associated with an excess risk of myocardial infarction in a large, prospective observational cohort of HIV-infected patients. Methods: We used Poisson regression models to quantify the relation between cumulative, recent (currently or within the preceding 6 months), and past use of zidovudine, didanosine, stavudine, lamivudine, and abacavir and development of myocardial infarction in 33 347 patients enrolled in the D:A:D study. We adjusted for cardiovascular risk factors that are unlikely…

AdultMalemedicine.medical_specialtyMyocardial Infarction610 Medicine & healthHIV Infections2700 General MedicinePharmacologyArticle10234 Clinic for Infectious DiseasesZidovudineAbacavirRisk FactorsInternal medicinemedicine80 and overHumansHIV InfectionMyocardial infarctionPoisson DistributionDidanosineAgedAged 80 and overbusiness.industryRisk FactorMedicine (all)StavudineLamivudineGeneral MedicineAbacavir/LamivudineMiddle Agedmedicine.diseaseDideoxynucleosideDideoxynucleosidesReverse Transcriptase InhibitorDidanosineCohortReverse Transcriptase InhibitorsFemalebusinessmedicine.drugHuman
researchProduct

“Evidence of HIV-1 second-generation recombinant strains (SGRs) in Sicily: sequence analysis of gag, pol, and env genes.”

2007

HIV-1Sicilysecond-generation recombinant strain
researchProduct

E' la pneumocistosi ancora presente in pazienti HIV positivi in epoca HAART?

2007

researchProduct

CD200 ANTIGEN IN B-CELL DERIVED NEOPLASMS: EXPRESSION AND CLINICAL IMPACT IN 77 CONSECUTIVE PATIENTS OF A SINGLE ISTITUTION

2012

cytofluorimetrylymphoprolyferative disease
researchProduct

PNEUMOCYSTIS JIROVECI PNEUMONIA IN HEMATOLOGICAL PATIENTS: A SINGLE INSTITUTION EXPERIENCE

2012

PJP infection Haematological neoplasmsSettore MED/15 - Malattie Del Sangue
researchProduct

CASO CLINICO

2006

researchProduct

RICERCA DI GIARDIA, CRYPTOSPORIDIUM E ISOSPORA IN SOGGETTI HIV POSITIVI

2004

researchProduct